Q-omics provides the consensus-scored POLR3E profile across patient tissues and cancer cell-line models. POLR3E expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, POLR3E is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, POLR3E RNA expression shows 20,509 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where POLR3E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3E survival associations across molecular data types. POLR3E RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3E RNA expression–survival associations across cancer types. High POLR3E expression shows unfavorable associations in KIRP, LGG, LIHC and BLCA, but favorable associations in BRCA and READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KIRP as the clearest survival context for POLR3E RNA expression.
This table summarizes POLR3E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR3E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3E shows lower tumor expression in THCA and higher tumor expression in COAD, KIRP, LIHC, LUAD and STAD. The COAD box plot shows higher POLR3E RNA expression in tumor versus normal tissue (log2 FC = +1.336, t-test p < 0.001).
This table shows molecular features associated with POLR3E in patient tissues and cancer cell lines. In patient samples, POLR3E shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR3E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
